UroVysion, urine cytology, and the College of American Pathologists: where should we go from here?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20670128.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Abstract UroVysion (Abbott Molecular Inc, Des Plaines, Illinois) is a US Food and Drug Administration-approved test for the diagnosis of urothelial carcinoma. Although widely used, there are a variety of different ways to evaluate and interpret the test, and questions remain about the test's cost effectiveness and reproducibility in actual clinical practice. I suggest that the College of American Pathologists has a unique opportunity to create educational programs focusing on borderline or difficult urine cytology and UroVysion samples to provide data upon which to make evidence-based decisions concerning the best use of these tests.
Medical subject headings
- Carcinoma, Transitional Cell
- Cytodiagnosis
- Urinalysis
- Urinary Bladder Neoplasms
- Urine